In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga: JB has performed consulting and/or advisory work for Grail, Roche, Lilly, Novartis. He has stock or other ownership interests in Grail.
Corrigendum: PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab (Annals of Oncology (2016) 27 (1519-1528) DOI: 10.1093/annonc/mdw197)
Guarneri V.;Conte P.;
2019
Abstract
In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga: JB has performed consulting and/or advisory work for Grail, Roche, Lilly, Novartis. He has stock or other ownership interests in Grail.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
